J Niederreiter, C Eck, T Ries, A Hartmann… - Frontiers in …, 2022 - frontiersin.org
… COVID-19-induced complement activation occurred via the lectinpathway, while activation of the alternative pathway … higher COVID-19 severity and mortality (21). However, evidence of …
NR Medjeral-Thomas, A Troldborg… - Frontiers in …, 2021 - frontiersin.org
… lectinpathway contributes to COVID-19 pathogenesis, we measured the plasma concentration of 11 lectin … Black crosses mark patient deaths. Coloured bars show when patients met …
MAS Malaquias, AC Gadotti… - Translational …, 2021 - Elsevier
… Despite the excessive number of deaths resulting from the current pandemic COVID-19, very few … Here, we described the massive activation of the lectinpathway, with consequences of …
, … of Health Research (CITIID-NIHR) COVID … - Frontiers in …, 2023 - frontiersin.org
… Despite this, genetic variations in MBL2 are not associated with susceptibility to SARS-CoV-2 infection or disease outcomes such as mortality and the development of Long COVID. …
AS Świerzko, M Cedzyński - Frontiers in Immunology, 2020 - frontiersin.org
… deaths than previously expected due to the pandemic of coronavirus disease 2019 (COVID-19), … called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Complement …
… therapy (RECOVERY) trial, demonstrated that dexamethasone reduced 28-day mortality in patients on invasive mechanical ventilation by 28.7 % (29.0 % versus 40.7 % with usual care)…
… significant morbidity and mortality, as well … lectinpathway of complement activation, binds to coronaviruses[5] and has been proposed to participate in the host defense during COVID-19 …
MP Götz, MO Skjoedt, R Bayarri-Olmos… - Journal of Innate …, 2023 - karger.com
… of coronavirus disease 2019 (COVID-19). To study a possible association between MASP-2 and COVID-19, … Survival was evaluated by 30-day mortality, meaning a 30-day follow-up on …
NJ Lynch, ACY Chan, YM Ali, P Khatri… - Clinical and …, 2022 - ncbi.nlm.nih.gov
… the activation of the lectinpathway ( S1 ). In March 2020, we conducted a small clinical study using narsoplimab to treat six patients with severe COVID‐19… showed mortality rates of 32% …